Half-year report · HY

Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedNo
Data checks12 of 12 passed
Key figures · 44
MetricValuePeriodScopeSource row
Revenue¥274m2026-01-01 → 2026-06-30StandaloneNet sales
Revenue¥593m2025-01-01 → 2025-12-31StandaloneNet sales (5-year summary)
Revenue¥252m2025-01-01 → 2025-06-30StandaloneNet sales
Operating income−¥480m2026-01-01 → 2026-06-30StandaloneOperating income
Operating income−¥537m2025-01-01 → 2025-06-30StandaloneOperating income
Ordinary income−¥482m2026-01-01 → 2026-06-30StandaloneOrdinary income
Ordinary income−¥989m2025-01-01 → 2025-12-31StandaloneOrdinary income loss (5-year summary)
Ordinary income−¥539m2025-01-01 → 2025-06-30StandaloneOrdinary income
Profit before tax−¥482m2026-01-01 → 2026-06-30StandaloneIncome before income taxes
Profit before tax−¥539m2025-01-01 → 2025-06-30StandaloneIncome before income taxes
Net income−¥483m2026-01-01 → 2026-06-30StandaloneProfit loss
Net income−¥983m2025-01-01 → 2025-12-31StandaloneNet income loss (5-year summary)
Net income−¥540m2025-01-01 → 2025-06-30StandaloneProfit loss
Total assets¥1.9bnat 2026-06-30StandaloneAssets
Total assets¥1.7bnat 2025-12-31StandaloneAssets
Total assets¥2.0bnat 2025-06-30StandaloneTotal assets (5-year summary)
Total liabilities¥341mat 2026-06-30StandaloneLiabilities
Total liabilities¥605mat 2025-12-31StandaloneLiabilities
Net assets / equity¥1.6bnat 2026-06-30StandaloneNet assets
Net assets / equity¥1.1bnat 2025-12-31StandaloneNet assets
Net assets / equity¥1.5bnat 2025-06-30StandaloneNet assets (5-year summary)
Cash and deposits¥1.4bnat 2026-06-30StandaloneCash and deposits
Cash and deposits¥1.2bnat 2025-12-31StandaloneCash and deposits
Cash & equivalents¥1.4bnat 2026-06-30StandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2025-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.5bnat 2025-06-30StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2024-12-31vStandaloneCash and cash equivalents
Operating cash flow−¥539m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in operating activities
Operating cash flow−¥936m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥673m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in operating activities
Investing cash flow−¥4m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in investment activities
Investing cash flow−¥55m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥710m2026-01-01 → 2026-06-30StandaloneNet cash provided by used in financing activities
Financing cash flow¥133m2025-01-01 → 2025-12-31StandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥85m2025-01-01 → 2025-06-30StandaloneNet cash provided by used in financing activities
EPS (basic)¥-6.622026-01-01 → 2026-06-30StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-14.472025-01-01 → 2025-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-7.972025-01-01 → 2025-06-30StandaloneBasic earnings loss per share (5-year summary)
Equity ratio81.9%at 2026-06-30StandaloneEquity to asset ratio (5-year summary)
Equity ratio64.1%at 2025-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio76.9%at 2025-06-30StandaloneEquity to asset ratio (5-year summary)
Shares issued78,940,200at 2026-06-30StandaloneTotal number of issued shares (5-year summary)
Shares issued68,453,800at 2025-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued68,053,800at 2025-06-30StandaloneTotal number of issued shares (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 16
SegmentItemPeriodValue
Reconciling Itemsreconcilingsegment profit2026-01-01 → 2026-06-30−¥269m
Drug Discovery And Developmentreportable segmentsegment profit2026-01-01 → 2026-06-30−¥369m
Drug Discovery Supportreportable segmentrevenue2026-01-01 → 2026-06-30¥274m
Drug Discovery Supportreportable segmentrevenue external2026-01-01 → 2026-06-30¥274m
Drug Discovery Supportreportable segmentsegment profit2026-01-01 → 2026-06-30¥159m
Total Of Reportable Segments And Otherssegment totalrevenue2026-01-01 → 2026-06-30¥274m
Total Of Reportable Segments And Otherssegment totalrevenue external2026-01-01 → 2026-06-30¥274m
Total Of Reportable Segments And Otherssegment totalsegment profit2026-01-01 → 2026-06-30−¥210m
Reconciling Itemsreconcilingsegment profit2025-01-01 → 2025-06-30−¥280m
Drug Discovery And Developmentreportable segmentsegment profit2025-01-01 → 2025-06-30−¥396m
Drug Discovery Supportreportable segmentrevenue2025-01-01 → 2025-06-30¥252m
Drug Discovery Supportreportable segmentrevenue external2025-01-01 → 2025-06-30¥252m
Drug Discovery Supportreportable segmentsegment profit2025-01-01 → 2025-06-30¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalrevenue external2025-01-01 → 2025-06-30¥252m
Total Of Reportable Segments And Otherssegment totalsegment profit2025-01-01 → 2025-06-30−¥257m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 430
ItemContextValueUnit
Interest expenses noeInterimDuration_NonConsolidatedMember605000JPY
Stock issuance cost noePrior1InterimDuration_NonConsolidatedMember1521000JPY
Stock issuance cost noeInterimDuration_NonConsolidatedMember2896000JPY
Other noePrior1InterimDuration_NonConsolidatedMember-JPY
Other noeInterimDuration_NonConsolidatedMember0JPY
Non operating expensesPrior1InterimDuration_NonConsolidatedMember3462000JPY
Non operating expensesInterimDuration_NonConsolidatedMember3502000JPY
Ordinary incomePrior1InterimDuration_NonConsolidatedMember-539020000JPY
Ordinary incomeInterimDuration_NonConsolidatedMember-481622000JPY
Gain on reversal of subscription rights to shares eiPrior1InterimDuration_NonConsolidatedMember350000JPY
Gain on reversal of subscription rights to shares eiInterimDuration_NonConsolidatedMember-JPY
Extraordinary incomePrior1InterimDuration_NonConsolidatedMember350000JPY
Extraordinary incomeInterimDuration_NonConsolidatedMember-JPY
Income before income taxesPrior1InterimDuration_NonConsolidatedMember-538670000JPY
Income before income taxesInterimDuration_NonConsolidatedMember-481622000JPY
Income taxes currentPrior1InterimDuration_NonConsolidatedMember1620000JPY
Income taxes currentInterimDuration_NonConsolidatedMember1620000JPY
Income taxesPrior1InterimDuration_NonConsolidatedMember1620000JPY
Income taxesInterimDuration_NonConsolidatedMember1620000JPY
Profit lossPrior1InterimDuration_NonConsolidatedMember-540290000JPY
Profit lossInterimDuration_NonConsolidatedMember-483242000JPY
Income before income taxesPrior1InterimDuration_NonConsolidatedMember-538670000JPY
Income before income taxesInterimDuration_NonConsolidatedMember-481622000JPY
Depreciation and amortization ope cfPrior1InterimDuration_NonConsolidatedMember-JPY
Depreciation and amortization ope cfInterimDuration_NonConsolidatedMember4831000JPY
Decrease increase in notes and accounts receivable trade ope cfPrior1InterimDuration_NonConsolidatedMember11689000JPY
Decrease increase in notes and accounts receivable trade ope cfInterimDuration_NonConsolidatedMember44364000JPY
Decrease increase in inventories ope cfPrior1InterimDuration_NonConsolidatedMember-495000JPY
Decrease increase in inventories ope cfInterimDuration_NonConsolidatedMember-23489000JPY
Decrease increase in advance payments ope cfPrior1InterimDuration_NonConsolidatedMember-2249000JPY
Decrease increase in advance payments ope cfInterimDuration_NonConsolidatedMember-23362000JPY
Decrease increase in consumption taxes refund receivable ope cfPrior1InterimDuration_NonConsolidatedMember8335000JPY
Decrease increase in consumption taxes refund receivable ope cfInterimDuration_NonConsolidatedMember14601000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1InterimDuration_NonConsolidatedMember9632000JPY
Increase decrease in notes and accounts payable trade ope cfInterimDuration_NonConsolidatedMember13818000JPY
Increase decrease in contract liabilities ope cfPrior1InterimDuration_NonConsolidatedMember-JPY
Increase decrease in contract liabilities ope cfInterimDuration_NonConsolidatedMember-69733000JPY
Increase decrease in accounts payable other ope cfPrior1InterimDuration_NonConsolidatedMember-75231000JPY
Increase decrease in accounts payable other ope cfInterimDuration_NonConsolidatedMember-6965000JPY
Increase decrease in accrued expenses ope cfPrior1InterimDuration_NonConsolidatedMember-18124000JPY
Increase decrease in accrued expenses ope cfInterimDuration_NonConsolidatedMember-2717000JPY
Other net ope cfPrior1InterimDuration_NonConsolidatedMember-64190000JPY
Other net ope cfInterimDuration_NonConsolidatedMember-6059000JPY
Subtotal ope cfPrior1InterimDuration_NonConsolidatedMember-669305000JPY
Subtotal ope cfInterimDuration_NonConsolidatedMember-536332000JPY
Interest income received ope cfPrior1InterimDuration_NonConsolidatedMember771000JPY
Interest income received ope cfInterimDuration_NonConsolidatedMember978000JPY
Interest expenses paid ope cf fin cfPrior1InterimDuration_NonConsolidatedMember-1940000JPY
Interest expenses paid ope cf fin cfInterimDuration_NonConsolidatedMember-605000JPY
Income taxes paid ope cfPrior1InterimDuration_NonConsolidatedMember-3240000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identitynon_consolidated 2025-12-31pass
balance sheet identitynon_consolidated 2026-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2025-12-31pass
statement vs summary · net assetsnon_consolidated 2026-06-30pass
statement vs summary · operating cash flownon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · operating cash flownon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · revenuenon_consolidated 2025-01-01/2025-06-30pass
statement vs summary · revenuenon_consolidated 2026-01-01/2026-06-30pass
statement vs summary · total assetsnon_consolidated 2025-12-31pass
statement vs summary · total assetsnon_consolidated 2026-06-30pass